47 Participants Needed

CT vs PET Scans for Coronary Artery Disease

CD
Overseen ByCarlo De Cecco
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion imaging (PET-MPI).

Research Team

CD

Carlo De Cecco, MD, PhD

Principal Investigator

Emory University

Eligibility Criteria

This trial is for individuals who need a CT scan to check for coronary artery disease and are willing to follow the study's procedures. They must not be pregnant, nursing, or have taken certain diabetes medications recently. People with implanted heart devices, severe allergies to contrast material used in scans, kidney issues, low blood pressure, or specific heart rhythm problems cannot participate.

Inclusion Criteria

Must be willing to comply with all clinical study procedures
Must provide written informed consent prior to any study-related procedures being performed
I am referred for a CT scan to check my heart's blood flow.

Exclusion Criteria

Pregnant or nursing females
Currently taking or has taken within 48 hours the following excluded medications: ActoPlus Met (Pioglitazone + metformin), Avandamet (Rosiglitazone + metformin), Fortamet (metformin), Glucovance (Glyburide +metformin), Glucophage (metformin), Glucophage extended-release (XR) (metformin), Glumetza (metformin), Janumet (Sitagliptin + metformin), Metformin, Metaglip (Glipizide + metformin), Riomet (metformin), Implanted rhythm devices (pacemaker, defibrillator), Acute psychiatric disorder, Unwilling to comply with the requirements of the protocol, Previously entered this study, Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study, Suffers from claustrophobia, Impaired renal function (GFR < 45 ml/min), Acute hypotension (<100 mm Hg systolic), 2nd or 3rd degree atrioventricular (AV) block

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging and Analysis

Participants undergo PET-MPI, CT-MPI, and CT-FFR imaging for analysis of myocardial perfusion and coronary flow

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after imaging procedures

4 weeks

Treatment Details

Interventions

  • CT-FFR
  • CT-MPI
  • PET-MPI Protocol
  • Regadenoson
Trial Overview The MATCH Investigation aims to compare two types of heart imaging tests: CT scans that measure blood flow and blockages in the heart arteries (CT-MPI and CT-FFR) against PET scans known as PET-MPI which is considered the gold standard.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Three imaging techniques: PET-MPI, CT-MPI, and CT-FFRExperimental Treatment4 Interventions
Participants referred for a clinical PET-MPI will also have CT-MPI and CT-FFR imaging performed for analysis of myocardial perfusion.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Emory University

Lead Sponsor

Trials
1,735
Recruited
2,605,000+

Siemens Medical Solutions

Industry Sponsor

Trials
26
Recruited
6,100+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security